Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G/A for HALOZYME THERAPEUTICS, INC. Common Stock (HALO).
- Disclosed ownership: 13%.
- Date of event: 31 Mar 2025.
BlackRock, Inc. - 31 Mar 2025 SCHEDULE 13G/A Report for HALOZYME THERAPEUTICS, INC. Common Stock (HALO)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- HALO
- Shares outstanding
- 123,237,893 shares
- Disclosed Ownership
- 16,144,164 shares
- Ownership
- 13%
- Form type
- SCHEDULE 13G/A
- Filing time
- 28 Apr 2025, 17:18:36 UTC
- Date of event
- 31 Mar 2025
- Next filing
- 17 Jul 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 13% ownership in HALOZYME THERAPEUTICS, INC. Common Stock (HALO) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 28 Apr 2025, 17:18.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13% | 16,144,164 | 15,945,228 | 0 | Spencer Fleming | Managing Director |